The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform
Huriye Balci - One of the best experts on this subject based on the ideXlab platform.
-
hereditary thrombophilia anti Beta2 Glycoprotein 1 igm and anti annexin v antibodies in recurrent pregnancy loss
American Journal of Reproductive Immunology, 2012Co-Authors: Suat Karata, Yavuz Aydin, Fahri Öçer, Aysenur Buyru, Huriye BalciAbstract:Citation Karata S, Aydin Y, Ocer F, Buyru A, Balci H. Hereditary Thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67: 251–255 Problem We investigated the Beta2-Glycoprotein I and anti-annexin V antibodies as anti-phospholipid–cofactor antibodies; and factor V G1691A Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations as hereditary thrombophilia in recurrent pregnancy losses (RPL). Method of study Study group consisted of 84 women with recurrent pregnancy loss and control group consisted of 84 women having at least one live birth. Results Methylenetetrahydrofolate reductase C677T homozygous mutation was detected in 28.5% of the study group and in 14.2% of the controls, and the difference was highly significant (P < 0.001). Heterozygous mutation of this gene was found in 64.3% of the study population and in 38.1% of the controls, and difference in heterozygous mutation frequency was also significant (P < 0.001). Both homozygous and heterozygous mutations of PT G20210A and factor V G1691A were not different between the groups. There was no significant difference in anti-annexin V levels and anti-Beta2-gp 1 levels of the groups. Conclusion We concluded that both homozygous and heterozygous mutations of MTHFR C677T were related with RPL in Caucasian women.
-
Hereditary thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss.
American Journal of Reproductive Immunology, 2011Co-Authors: Suat Karata, Yavuz Aydin, Fahri Öçer, Aysenur Buyru, Huriye BalciAbstract:Citation Karata S, Aydin Y, Ocer F, Buyru A, Balci H. Hereditary Thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67: 251–255 Problem We investigated the Beta2-Glycoprotein I and anti-annexin V antibodies as anti-phospholipid–cofactor antibodies; and factor V G1691A Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations as hereditary thrombophilia in recurrent pregnancy losses (RPL). Method of study Study group consisted of 84 women with recurrent pregnancy loss and control group consisted of 84 women having at least one live birth. Results Methylenetetrahydrofolate reductase C677T homozygous mutation was detected in 28.5% of the study group and in 14.2% of the controls, and the difference was highly significant (P
Suat Karata - One of the best experts on this subject based on the ideXlab platform.
-
hereditary thrombophilia anti Beta2 Glycoprotein 1 igm and anti annexin v antibodies in recurrent pregnancy loss
American Journal of Reproductive Immunology, 2012Co-Authors: Suat Karata, Yavuz Aydin, Fahri Öçer, Aysenur Buyru, Huriye BalciAbstract:Citation Karata S, Aydin Y, Ocer F, Buyru A, Balci H. Hereditary Thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67: 251–255 Problem We investigated the Beta2-Glycoprotein I and anti-annexin V antibodies as anti-phospholipid–cofactor antibodies; and factor V G1691A Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations as hereditary thrombophilia in recurrent pregnancy losses (RPL). Method of study Study group consisted of 84 women with recurrent pregnancy loss and control group consisted of 84 women having at least one live birth. Results Methylenetetrahydrofolate reductase C677T homozygous mutation was detected in 28.5% of the study group and in 14.2% of the controls, and the difference was highly significant (P < 0.001). Heterozygous mutation of this gene was found in 64.3% of the study population and in 38.1% of the controls, and difference in heterozygous mutation frequency was also significant (P < 0.001). Both homozygous and heterozygous mutations of PT G20210A and factor V G1691A were not different between the groups. There was no significant difference in anti-annexin V levels and anti-Beta2-gp 1 levels of the groups. Conclusion We concluded that both homozygous and heterozygous mutations of MTHFR C677T were related with RPL in Caucasian women.
-
Hereditary thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss.
American Journal of Reproductive Immunology, 2011Co-Authors: Suat Karata, Yavuz Aydin, Fahri Öçer, Aysenur Buyru, Huriye BalciAbstract:Citation Karata S, Aydin Y, Ocer F, Buyru A, Balci H. Hereditary Thrombophilia, anti-Beta2 Glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67: 251–255 Problem We investigated the Beta2-Glycoprotein I and anti-annexin V antibodies as anti-phospholipid–cofactor antibodies; and factor V G1691A Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations as hereditary thrombophilia in recurrent pregnancy losses (RPL). Method of study Study group consisted of 84 women with recurrent pregnancy loss and control group consisted of 84 women having at least one live birth. Results Methylenetetrahydrofolate reductase C677T homozygous mutation was detected in 28.5% of the study group and in 14.2% of the controls, and the difference was highly significant (P
Elisabet Svenungsson - One of the best experts on this subject based on the ideXlab platform.
-
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study
Arthritis Research & Therapy, 2012Co-Authors: Johanna T Gustafsson, Julia F Simard, Iva Gunnarsson, Kerstin Elvin, Ingrid E Lundberg, Lars-olof Hansson, Anders Larsson, Elisabet SvenungssonAbstract:Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Cardiovascular disease (CVD) is common and a major cause of mortality. Studies on cardiovascular morbidity are abundant, whereas mortality studies focusing on cardiovascular outcomes are scarce. The aim of this study was to investigate causes of death and baseline predictors of overall (OM), non-vascular (N-VM), and specifically cardiovascular (CVM) mortality in SLE, and to evaluate systematic coronary risk evaluation (SCORE). Methods 208 SLE patients were included 1995-1999 and followed up after 12 years. Clinical evaluation, CVD risk factors, and biomarkers were recorded at inclusion. Death certificates and autopsy protocols were collected. Causes of death were divided into CVM (ischemic vascular and general atherosclerotic diseases), N-VM and death due to pulmonary hypertension. Predictors of mortality were investigated using multivariable Cox regression. SCORE and standardized mortality ratio (SMR) were calculated. Results During follow-up 42 patients died at mean age of 62 years. SMR 2.4 (CI 1.7-3.0). 48% of deaths were caused by CVM. SCORE underestimated CVM but not to a significant level. Age, high cystatin C levels and established arterial disease were the strongest predictors for all- cause mortality. After adjusting for these in multivariable analyses, only smoking among traditional risk factors, and high soluble vascular cell adhesion molecule-1 (sVCAM-1), high sensitivity C-reactive protein (hsCRP), anti-Beta2 Glycoprotein-1 (aBeta2GP1) and any antiphospholipid antibody (aPL) among biomarkers, remained predictive of CVM. Conclusion With the exception of smoking, traditional risk factors do not capture the main underlying risk factors for CVM in SLE. Rather, cystatin C levels, inflammatory and endothelial markers, and antiphospholipid antibodies (aPL) differentiate patients with favorable versus severe cardiovascular prognosis. Our results suggest that these new biomarkers are useful in evaluating the future risk of cardiovascular mortality in SLE patients.
Richard F Hamman - One of the best experts on this subject based on the ideXlab platform.
-
association of antibodies to Beta2 Glycoprotein 1 with pregnancy loss and pregnancy induced hypertension a prospective study in low risk pregnancy
Obstetrics & Gynecology, 1999Co-Authors: Anne M Lynch, Tim Byers, Woodruff Emlen, Dawn Rynes, Susan M Shetterly, Richard F HammanAbstract:Abstract Objective: To determine whether higher levels of anti-β2-Glycoprotein 1 before 25 weeks’ gestation are independently associated with either pregnancy loss or pregnancy-induced hypertension. Methods: Serum samples for the immunoglobulin (Ig) G and IgM isotypes of anti-β2-Glycoprotein 1, anticardiolipin antibody, and antiphosphatidylserine were collected from 325 low-risk nulliparas who presented for prenatal care before 25 weeks’ gestation. This cohort was followed prospectively for the development of pregnancy loss and pregnancy-induced hypertension. Results: The adjusted odds ratios (OR) and 95% confidence intervals (CI) of elevated antiphospholipid antibody levels for pregnancy loss were: IgG anti-β2-Glycoprotein 1, OR 1.2 (CI 0.5, 2.8); IgG anticardiolipin antibody, OR 8.4 (CI 2.3, 31); and IgG antiphosphatidylserine, OR 5.2 (CI 1.4, 18.7). The relative risks of pregnancy loss for all IgG antiphospholipid antibodies were higher among women who had blood collected after 10 weeks’ gestation compared with those studied before 10 weeks’ gestation. However, there were only marginal differences in the attributable risks, suggesting that the impact of elevated levels of antiphospholipid antibodies might be similar in early and later stages of pregnancy. None of the antiphospholipid antibodies was associated with pregnancy-induced hypertension. Conclusion: In this study, elevated levels of IgG anticardiolipin and IgG antiphosphatidylserine antibodies were markers of pregnancy loss, but an elevated level of anti-β2-Glycoprotein was not a strong predictor of fetal loss.
Yongzhe Li - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the diagnostic potential of antibodies to Beta2 Glycoprotein 1 domain 1 in chinese patients with antiphospholipid syndrome
Scientific Reports, 2016Co-Authors: Shulan Zhang, Ziyan Wu, Si Chen, Jing Li, Liubing Li, Wen Zhang, Jiuliang Zhao, Fengchun Zhang, Yongzhe LiAbstract:In this study, we evaluated the clinical performance of anti-β2-Glycoprotein 1 domain 1 antibodies (aβ2GP1-D1) in the diagnosis of antiphospholipid syndrome (APS). Sera from 229 subjects were tested, including 35 patients with primary APS, 51 patients with APS associated to other diseases, 30 patients with non-APS thrombosis, 32 patients with non-APS pregnancy-related morbidity, 42 patients with systemic lupus erythematosus and 39 healthy controls (HC). Serum IgG aβ2GP1-D1, IgG/IgM anti-cardiolipin (aCL) and IgG/IgM aβ2GP1 were measured by a chemiluminescence assay. The levels of IgG aβ2GP1-D1 were significantly increased in patients with APS, compared with disease controls and HCs (p < 0.001). Significant correlation was identified between IgG aβ2GP1-D1 and IgG aβ2GP1 (p < 0.0001), indicating IgG aβ2GP1-D1 were the predominant domain-specific antibodies in IgG aβ2GP1 family. Importantly, aβ2GP1-D1, but not aβ2GP1 non-D1, was significantly correlated with thrombotic events. Interestingly, no significant correlation between IgG aβ2GP1-D1 and obstetric complications was observed. Additionally, significantly higher levels of IgG aβ2GP1-D1 were found in patients with triple aPL positivity, compared with patients with double and single aPL positivity. Our findings suggest a potential role of IgG aβ2GP1-D1 in identifying APS patients with high risk of thrombosis, shedding insight on the introduction of IgG aβ2GP1-D1 in China.
-
Evaluation of the diagnostic potential of antibodies to Beta2-Glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome.
Scientific Reports, 2016Co-Authors: Shulan Zhang, Ziyan Wu, Si Chen, Jing Li, Liubing Li, Wen Zhang, Jiuliang Zhao, Fengchun Zhang, Yongzhe LiAbstract:In this study, we evaluated the clinical performance of anti-β2-Glycoprotein 1 domain 1 antibodies (aβ2GP1-D1) in the diagnosis of antiphospholipid syndrome (APS). Sera from 229 subjects were tested, including 35 patients with primary APS, 51 patients with APS associated to other diseases, 30 patients with non-APS thrombosis, 32 patients with non-APS pregnancy-related morbidity, 42 patients with systemic lupus erythematosus and 39 healthy controls (HC). Serum IgG aβ2GP1-D1, IgG/IgM anti-cardiolipin (aCL) and IgG/IgM aβ2GP1 were measured by a chemiluminescence assay. The levels of IgG aβ2GP1-D1 were significantly increased in patients with APS, compared with disease controls and HCs (p
-
evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti Beta2 Glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome
Medicine, 2015Co-Authors: Shulan Zhang, Ziyan Wu, Fengchun Zhang, Ping Li, Yongzhe LiAbstract:Detection of antiphospholipid antibodies represents the first-line approach for diagnosis of antiphospholipid syndrome (APS). In this study, we evaluated the clinical performance of a novel chemiluminescence assay (CIA) in detection of IgG/IgM/IgA anti-cardiolipin (aCL) and IgG/IgM/IgA anti-β2 Glycoprotein 1 (aβ2GP1) antibodies and to compare it with commercial enzyme-linked immunosorbent assay (ELISA) kits from the same manufacturer. A total of 227 sera were tested in this study, including 84 samples from patients with APS, 104 samples from patients with non-APS diseases as disease controls, and 39 healthy controls. Serum IgG/IgM/IgA aCL and IgG/IgM/IgA aβ2GP1 were determined by both ELISA (QUANTA Lite™ ELISA) and CIA (QUANTA Flash®assays). Significant quantitative correlations were identified between ELISA and CIA in IgG/IgM/IgA aCL and IgG/IgM/IgA aβ2GP1 autoantibodies detection (P < 0.001), with the rho value ranging from 0.51 to 0.87. In addition, ELISA and CIA demonstrated good qualitative agreements in IgG/IgM/IgA aCL and IgM/IgA aβ2GP1 autoantibodies determination with kappa coefficient ranged from 0.52 to 0.77. In contrast, ELISA and CIA showed a moderate qualitative agreement in IgG aβ2GP1 detection with a kappa value of 0.2. Notably, significantly higher IgG aβ2GP1 positive sera were detected by CIA, compared to those detected by ELISA in both primary APS (52.9% vs. 8.8%) and APS associated to other diseases sera (70.0% vs. 8.0%). For diagnosis of APS, IgG aβ2GP1 detection by CIA (IgG aβ2GP1 CIA) demonstrated the highest sensitivity (63.1%), followed by IgG aCL CIA (48.8%). More importantly, IgG aβ2GP1 CIA demonstrated the highest ability to predict the thrombotic events in patients with APS, with an OR of 3 (95% CI: 1.1–7.9). Our data suggest that this novel CIA assay had good performance in detecting aCL and aβ2GP1 antibodies, especially in the detection of IgG aβ2GP1 antibodies. Our findings could shed insight on the application of CIA in the laboratory diagnosis of APS in China.
-
Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome
Medicine, 2015Co-Authors: Shulan Zhang, Ziyan Wu, Fengchun Zhang, Ping Li, Yongzhe LiAbstract:Detection of antiphospholipid antibodies represents the first-line approach for diagnosis of antiphospholipid syndrome (APS). In this study, we evaluated the clinical performance of a novel chemiluminescence assay (CIA) in detection of IgG/IgM/IgA anti-cardiolipin (aCL) and IgG/IgM/IgA anti-β2 Glycoprotein 1 (aβ2GP1) antibodies and to compare it with commercial enzyme-linked immunosorbent assay (ELISA) kits from the same manufacturer. A total of 227 sera were tested in this study, including 84 samples from patients with APS, 104 samples from patients with non-APS diseases as disease controls, and 39 healthy controls. Serum IgG/IgM/IgA aCL and IgG/IgM/IgA aβ2GP1 were determined by both ELISA (QUANTA Lite™ ELISA) and CIA (QUANTA Flash®assays). Significant quantitative correlations were identified between ELISA and CIA in IgG/IgM/IgA aCL and IgG/IgM/IgA aβ2GP1 autoantibodies detection (P
